Description
The Urine CrossLaps ® EIA is an enzyme immunosorbent assay for quantitative determination of degradation products of C-terminal telopeptides of Type-I collagen in human urine.
· Prediction of long-term skeletal response to anti-resorptive therapies
· Patient motivation and compliance
· Assessment of bone resorption in patients
· Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone1. During renewal of the skeleton, type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can be measured by the Urine CrossLaps ® EIA and has been reported as a useful tool for follow up of anti-resorptive treatment of patients with metabolic bone diseases.
|
Code |
|
|
Format |
96 Wells |
|
Methodology |
EIA |
|
Number of Tests per Kit |
40 in duplicate |
|
Standards |
6 |
|
Controls |
2 |
|
Specimen Type |
Urine |
|
Specimen Volume |
15 µL |
|
Detection Limit |
50 µg/L |
|
Assay Range |
approx 0 - 6750 ug/L |
|
Precision |
CV's between runs <6% CV's within run <10% |
1. 1. Bjarnason et al., Bone 26, 561-569 (2000)
